An Adaptive Program of IKT-001 in Pulmonary Arterial Hypertension (PAH)
Trial details
- Registry ID
- NCT07365332
- Drugs studied
- IKT-001
TrialRedline tracks 2 clinical trials sponsored by Inhibikase Therapeutics: 2 Phase 3.
Company identity has not yet been verified
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| An Adaptive Program of IKT-001 in Pulmonary Arterial Hypertension (PAH)NCT07365332 | IKT-001 | Recruiting | 2029-06Estimated |
| Open-Label Study of IKT-001 in Pulmonary Arterial Hypertension (PAH)NCT07632898 | IKT-001 | Not yet recruiting | 2030-06-30Estimated |
Names as written in the registry records.
NCT07365332 · Inhibikase Therapeutics
Before: Not yet recruiting. After: Recruiting.
NCT07365332 · Inhibikase Therapeutics
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: [Part A] To evaluate the effect on PVR in participants with WHO Group 1 PAH treated with IKT-001 compared to placebo Measure: [Part B] To characterize the effects of IKT-001 on symptoms and characteristics of Pulmonary Arterial Hypertension compared to placebo. After: Measure: [Part A] To evaluate the effect on Pulmonary Vascular Resistance (PVR) in participants with WHO Group 1 PAH treated with IKT-001 compared to placebo Measure: [Part B] To characterize the effects of IKT-001 on symptoms and characteristics of Pulmonary Arterial Hypertension compared to placebo.